…A systematic review of mirtazapine treatment trials has found that there is inadequate reporting of adverse events in therapeutic trials of major depression (Watanabe et al. CNS Drugs 2010; 24: 35-53). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…ts with Parkinson’s disease (Zesiewicz et al. Neurology 2010; 74: 924-931; free full text at www.neurology.org/cgi/reprint/74/11/924). Nonmotor symptoms addressed included sleep disorders (restless legs syndrome, periodic limb movements of sleep, excessive daytime somnolence, insomnia, REM sleep behaviour disorder), autonomic dysfunction (GI disorders, orthostatic hypotension, sexual dysfunction, urinary incontinence), fatigue and anxiety. Subscri…
…A U.S. study reports that the beneficial effects of treating depression in older patients extend to caregivers (Martire et al. J Am Geriatr Soc 2010; 58: 23-29; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC2872092/?tool=pubmed). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…afety and efficacy of mitoxantrone in multiple sclerosis, concluding that the risks of systolic dysfunction and therapy-related leukemia are higher than previously estimated (Marriott et al. Neurology 2010; 74: 1463-1470; free full text at www.neurology.org/cgi/reprint/74/18/1463). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
…REPORT FROM THE AAN, APRIL 10-17, 2010 – In 2008, Italian researchers reported that lithium 300-450 mg/day delayed disease progression in amyotrophic lateral sclerosis (Fornai et al. PNAS 2008; 105: 2052-2057; free full text at www.ncbi.nlm.nih.gov/pmc/articles/PMC2538879/?tool=pubmed). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…